POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

Bibliographic Details
Main Authors: M. Dimopoulos, K. Weisel, P. Moreau, L.D.A. Jr, D. White, J.S. Miguel, P. Sonneveld, M. Engelhardt, M. Jenner, A. Corso, J. Dürig, M. Pavic, M. Salomo, E. Casal, R. Jiang, T. Nguyen, T. Peluso, P. Richardson
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137920307409

Internet

http://www.sciencedirect.com/science/article/pii/S2531137920307409

Similar Items